The video version of this podcast can be found here: · https://youtu.be/kYcJ3Ym3C0AThis episode makes reference to guidelines produced by the "National Institute for Health and Care Excellence" in the UK, also referred to as "NICE". The content on this channel reflects my professional interpretation/summary of the guidance and I am in no way affiliated with, employed by or funded/sponsored by NICE.My name is Fernando Florido and I am a General Practitioner in the United Kingdom. In this episode I go through new and updated recommendations published in July 2024 by the National Institute for Health and Care Excellence (NICE), focusing on those that are relevant to Primary Care only. There were no updated guidelines or quality standards but, apart from some radiotherapy treatments, there were five technology appraisals, none of which were really relevant to Primary care. However, I give them a very quick overview I am not giving medical advice; this video is intended for health care professionals, it is only my summary and my interpretation of the guidelines and you must use your clinical judgement. There is a podcast version of this and other videos that you can access here: Primary Care guidelines podcast: · Redcircle: https://redcircle.com/shows/primary-care-guidelines· Spotify: https://open.spotify.com/show/5BmqS0Ol16oQ7Kr1WYzupK· Apple podcasts: https://podcasts.apple.com/gb/podcast/primary-care-guidelines/id1608821148 There is a YouTube version of this and other videos that you can access here: The Practical GP YouTube Channel: https://youtube.com/@practicalgp?si=ecJGF5QCuMLQ6hrk The Full NICE News bulletin for July 2024 can be found here:· https://www.nice.org.uk/guidance/published?from=2024-07-01&to=2024-07-31&ndt=Guidance&ndt=Quality+standard The links to the current consultations can be found here:Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over:· https://www.nice.org.uk/guidance/ta986/chapter/1-RecommendationsTenecteplase for treating acute ischaemic stroke:· https://www.nice.org.uk/guidance/ta990/chapter/1-RecommendationsIvacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis:· https://www.nice.org.uk/guidance/ta988/chapter/1-RecommendationsEtranacogene dezaparvovec for treating moderately severe or severe haemophilia B:· https://www.nice.org.uk/guidance/ta989/chapter/1-RecommendationTrastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy:· https://www.nice.org.uk/guidance/ta992/chapter/1-RecommendationsIntro / outro music: Track: Halfway Through — Broke In Summer [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/aBGk6aJM3IU Free Download / Stream: https://alplus.io/halfway-through TranscriptIf you are listening to this podcast on YouTube, for a better experience, switch to the video version. The link is in the top right corner of the video and in the episode description.Hello and welcome, I am Fernando, a GP in the UK. Today, we are looking at the NICE updates published in July 2024. This month we have not had any new guidelines or quality standards but we have had a few new technology appraisals, that is, when NICE reviews new treatments to decide whether they should be recommended on the NHS. Apart from some radiotherapy recommendations, there were 5 other new treatments. Although none of them were really relevant to Primary care, I will give you a very quick overview so that we understand where new therapies are coming from and so that we have some knowledge if we come across them. But do not worry, it is a real summary, and today will be a very brief episode. So, let’s jump into it. The first area refers to the treatment of moderate to severe atopic dermatitis or eczema.We know that standard treatment includes the topical use of emollients and steroids. If these treatments are not effective, systemic immunosuppressant treatments such as ciclosporin and methotrexate can be added. If there is an inadequate response or they are unsuitable, other agents such as a Janus kinase (JAK) inhibitor or a biological medicine (such as dupilumab or tralokinumab) can be used.NICE has evaluated a new biological medicine alternative, lebrikizumab and indirect comparisons with Janus Kinase inhibitors and other biological treatments suggest that it is equally effective at an acceptable cost.The biological treatments lebrikizumab, dupilumab, and tralokinumab are monoclonal antibodies that inhibit interleukin processes, thus reducing inflammation and modulating the immune response in conditions such as eczema and asthma. They are administered via subcutaneous injection and they can now all be used as treatment options.The next area covers the treatment of acute ischaemic ...
